Wed, Apr 17, 2024
Through the new Fund IHF, it has made its maiden investment of $2 million in Mynvax, a biotech start-up focused on developing novel recombinant vaccines for human respiratory viral diseases, including seasonal influenza and COVID-19.
More >
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
